| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BillionToOne, Inc. Class A Common Stock$149.97
-35.25 (-24.78%)
Market Cap
6.22 B
EPS
0.96
P/E Ratio
156.22 $
Value Trade
95.01 M
SEC Financials
Q1 2026Dilution Risk
Revenue
108.39 M
R&D Expenses
14.69 M
Operating CF
15.43 M
Total Assets
700.73 M
Total Liabilities
195.11 M
Equity
505.62 M
13.17 %
Week
21.53 %
1 Month
84.24 %
3 Month
79.58 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
537.45 M
Monthly Burn
-
Runway
-
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
918.21 K
52 Week Range
61.96 - 138.70
% held by Insiders
51.36 %
% held by Institutions
17.89 %
Enterprise Value
5.77 B
Total Shares
41.45 M
Short %
10.76 %
Float Shares
20.15 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BillionToOne, Inc. Class A Common Stock
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
TBD
▲PublicationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BLLN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BLLN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-BLLN
Aug 5, 2026▼ -24.8%today
BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
BillionToOne, Inc. reported a strong financial performance for Q2 2026, with total revenue reaching $109.4 million, a 64% increase from the previous year. The company reiterated its revenue guidance for the full year, expecting between $450 million to $465 million. Key operational highlights include the upcoming launch of an expanded fetal risk screening panel and an add-on feature for its Northstar Select test.
Read more →-BLLN
Jul 20, 2026BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar
BillionToOne has appointed Dr. Ethan Dmitrovsky as Chief Medical Officer for Oncology, aiming to enhance its Northstar liquid biopsy portfolio. Dr. Dmitrovsky, a prominent figure in cancer research, will focus on expanding clinical adoption and guiding treatment decisions for patients with solid tumors. His leadership is expected to drive growth and innovation within the company.
Read more →-BLLN
Jul 15, 2026BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026
BillionToOne, Inc. (NASDAQ: BLLN) will announce its second quarter financial results for 2026 on August 5, 2026, after market close. A conference call is scheduled for the same day at 1:30 PM PT to discuss these results. The company is known for its innovative molecular diagnostics technology.
Read more →-BLLN
Jun 29, 2026BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
BillionToOne's Northstar Response assay has been shown to be a more effective predictor of survival for cancer patients undergoing immunotherapy compared to standard imaging methods. In a peer-reviewed study involving 142 patients across various tumor types, it was found that combining molecular monitoring with imaging significantly enhances predictive accuracy. The assay allows for earlier detection of disease progression, potentially improving patient management.
Read more →-BLLN
May 27, 2026▲ +7.7%on this news
BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
BillionToOne, Inc. will participate in the William Blair 46th Annual Growth Stock Conference on June 2, 2026. Management is scheduled to present from 12:40 PM to 1:10 PM Central Time. The event will feature a live and archived webcast available on the company's investor relations website.
Read more →-BLLN
May 6, 2026BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance
BillionToOne, Inc. reported strong financial results for Q1 2026, with total revenue reaching $108.4 million, an 84% increase from the previous year. The company also launched a new prenatal testing assay, Unity ConfirmTM, and raised its full-year revenue guidance to between $450 million and $465 million. The significant growth reflects the company's expanding market presence and product offerings.
Read more →-BLLN
Apr 15, 2026BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026
BillionToOne, Inc. will announce its financial results for Q1 2026 on May 6, 2026. The results will be shared after market close, followed by a conference call at 1:30 PM PT. Analysts are encouraged to register in advance for the call, which will also be available via a live and archived webcast.
Read more →-BLLN
Mar 5, 2026▼ -10.7%on this news
BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance
BillionToOne, Inc. reported impressive financial results for Q4 and full year 2025, showcasing a 113% revenue increase in Q4 compared to the previous year. The company also raised its revenue guidance for 2026, projecting growth of 41% to 46%. With strong performance in prenatal and oncology testing, BillionToOne is optimistic about its future prospects.
Read more →-BLLN
Feb 17, 2026▲ +5.2%on this news
BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
BillionToOne, Inc. has announced it will release its financial results for the fourth quarter and full year of 2025 on March 4, 2026. The results will be shared after market close, followed by a conference call at 1:30 PM PT. This event highlights the company's commitment to transparency and investor communication.
Read more →-BLLN
Feb 10, 2026BillionToOne Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, Extending Its Leadership In Setting the New Standard in Prenatal Care
BillionToOne has launched the UNITY expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, enhancing prenatal care for conditions like Hemolytic Disease of the Fetus and Newborn (HDFN) and Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). These non-invasive tests provide early and accurate fetal antigen status, significantly improving clinical decision-making. The new offerings are expected to reshape standards of care in affected pregnancies.
Read more →-BLLN
Dec 24, 2025BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference
BillionToOne, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2026. Management will present from 9:45am to 10:25am Pacific Time. A live and archived webcast will be available on their investor relations website. The company aims to provide powerful and accurate molecular diagnostics.
Read more →Competitive Position
How BLLN ranks across every disease it competes inCompetitive Position is a premium feature
See how BLLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial